Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.

Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, Kieffer TL, Leopold L.

Antivir Ther. 2018;23(4):335-344. doi: 10.3851/IMP3212.

PMID:
29244026
2.

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.

Haseltine EL, Kimko H, Luo H, Tolsma J, Bartels DJ, Kieffer TL, Garg V.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):681-98. doi: 10.1007/s10928-015-9435-z. Epub 2015 Aug 20.

PMID:
26289844
3.

A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants.

Ho CKY, Welkers MRA, Thomas XV, Sullivan JC, Kieffer TL, Reesink HW, Rebers SPH, de Jong MD, Schinkel J, Molenkamp R.

J Virol Methods. 2015 Jul;219:28-37. doi: 10.1016/j.jviromet.2015.03.018. Epub 2015 Mar 26.

PMID:
25818622
4.

Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

Haseltine EL, Penney MS, George S, Kieffer TL.

J Viral Hepat. 2015 Sep;22(9):701-7. doi: 10.1111/jvh.12382. Epub 2015 Jan 13.

PMID:
25582683
5.

Modeling viral evolutionary dynamics after telaprevir-based treatment.

Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC.

PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014 Aug.

6.

Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.

Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O, Bartels DJ, Rao BG, Rijnbrand R, Kieffer TL.

Antimicrob Agents Chemother. 2014 Sep;58(9):5456-65. doi: 10.1128/AAC.03052-14. Epub 2014 Jun 30.

7.

Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.

Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, Picchio G, De Meyer S.

J Infect Dis. 2014 Dec 15;210(12):1871-80. doi: 10.1093/infdis/jiu340. Epub 2014 Jun 18.

PMID:
24943725
8.

Resistance to hepatitis C virus protease inhibitors.

Kieffer TL, George S.

Curr Opin Virol. 2014 Oct;8:16-21. doi: 10.1016/j.coviro.2014.04.008. Epub 2014 May 21. Review.

PMID:
24852142
9.

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM.

J Clin Gastroenterol. 2015 Apr;49(4):336-44. doi: 10.1097/MCG.0000000000000150.

PMID:
24828357
10.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C.

J Clin Virol. 2014 Mar;59(3):148-55. doi: 10.1016/j.jcv.2013.12.011. Epub 2014 Jan 6.

PMID:
24462470
11.

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.

Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL.

Antimicrob Agents Chemother. 2013 Dec;57(12):6236-45. doi: 10.1128/AAC.01578-13. Epub 2013 Oct 7.

12.

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL.

Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10.

PMID:
23575197
13.

Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples.

Zhang EZ, Bartels DJ, Frantz JD, Seepersaud S, Lippke JA, Shames B, Zhou Y, Lin C, Kwong A, Kieffer TL.

Virol J. 2013 Feb 12;10:53. doi: 10.1186/1743-422X-10-53.

14.

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G.

Clin Gastroenterol Hepatol. 2013 Feb;11(2):193-5. doi: 10.1016/j.cgh.2012.10.045. Epub 2012 Nov 14.

PMID:
23159528
15.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL.

J Virol. 2013 Feb;87(3):1544-53. doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14.

16.

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.

Sullivan JC, Zhang EZ, Bartels DJ, Tigges A, Dorrian JL, Kwong AD, Kieffer TL.

Virol J. 2012 Aug 6;9:147. doi: 10.1186/1743-422X-9-147.

17.

Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.

Thomas XV, de Bruijne J, Sullivan JC, Kieffer TL, Ho CK, Rebers SP, de Vries M, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J.

PLoS One. 2012;7(7):e41191. doi: 10.1371/journal.pone.0041191. Epub 2012 Jul 27.

18.

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G.

Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962.

PMID:
22806681
19.

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.

PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12.

20.

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.

Adiwijaya BS, Kieffer TL, Henshaw J, Eisenhauer K, Kimko H, Alam JJ, Kauffman RS, Garg V.

PLoS Comput Biol. 2012 Jan;8(1):e1002339. doi: 10.1371/journal.pcbi.1002339. Epub 2012 Jan 5.

21.

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.

de Bruijne J, Sullivan JC, Kieffer TL, Botfield M, Shames B, Schinkel J, Molenkamp R, Weegink C, Reesink H.

J Clin Virol. 2012 Feb;53(2):174-7. doi: 10.1016/j.jcv.2011.11.004. Epub 2011 Dec 3.

PMID:
22138301
22.

HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.

Lange CM, Susser S, Herrmann E, Karey U, Kieffer TL, Kwong AD, Schinkel J, Reesink HW, Zeuzem S, Sarrazin C.

Scand J Gastroenterol. 2011 Nov;46(11):1362-8. doi: 10.3109/00365521.2011.605465. Epub 2011 Aug 5.

PMID:
21815864
23.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

24.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG).

Gastroenterology. 2011 Mar;140(3):755-60. doi: 10.1053/j.gastro.2011.01.029. Epub 2011 Jan 19. No abstract available.

PMID:
21255574
25.

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

Kieffer TL, Kwong AD, Picchio GR.

J Antimicrob Chemother. 2010 Feb;65(2):202-12. doi: 10.1093/jac/dkp388. Epub 2009 Nov 10. Review.

PMID:
19903720
26.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.

J Infect Dis. 2008 Sep 15;198(6):800-7. doi: 10.1086/591141.

PMID:
18637752
27.

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG.

J Hepatol. 2008 Aug;49(2):163-9. doi: 10.1016/j.jhep.2008.03.027. Epub 2008 Apr 29.

PMID:
18486984
28.

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S.

Hepatology. 2007 Sep;46(3):640-8.

PMID:
17879366
29.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S.

Hepatology. 2007 Sep;46(3):631-9.

PMID:
17680654
30.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD.

Gastroenterology. 2007 May;132(5):1767-77. Epub 2007 Feb 21.

PMID:
17484874
31.

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, Carson KA, Siliciano RF, Flexner C.

Clin Infect Dis. 2006 Apr 15;42(8):1189-96. Epub 2006 Mar 7. Erratum in: Clin Infect Dis. 2006 Sep 1;43(5):672.

PMID:
16575741
32.

HIV-1 viral load blips are of limited clinical significance.

Lee PK, Kieffer TL, Siliciano RF, Nettles RE.

J Antimicrob Chemother. 2006 May;57(5):803-5. Epub 2006 Mar 13.

PMID:
16533823
33.

Update on HIV-1 viral load blips.

Nettles RE, Kieffer TL.

Curr Opin HIV AIDS. 2006 Mar;1(2):157-61. doi: 10.1097/01.COH.0000203834.24221.13.

PMID:
19372801
34.

Clinical implications of HIV viral load blips.

Kieffer TL, Nettles RE.

Hopkins HIV Rep. 2005 Jul;17(4):8-9. No abstract available.

PMID:
16419309
35.

A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.

Monie D, Simmons RP, Nettles RE, Kieffer TL, Zhou Y, Zhang H, Karmon S, Ingersoll R, Chadwick K, Zhang H, Margolick JB, Quinn TC, Ray SC, Wind-Rotolo M, Miller M, Persaud D, Siliciano RF.

J Virol. 2005 Apr;79(8):5185-202.

36.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF.

JAMA. 2005 Feb 16;293(7):817-29.

PMID:
15713771
37.
38.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF.

Clin Infect Dis. 2004 Oct 1;39(7):1030-7. Epub 2004 Sep 1.

PMID:
15472857
39.

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.

Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, Persaud D, Siliciano RF.

J Infect Dis. 2004 Apr 15;189(8):1452-65. Epub 2004 Apr 5.

PMID:
15073683
40.
41.

Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.

Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF.

J Virol. 2002 Sep;76(17):8518-31.

42.

Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication.

Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF.

J Virol. 2002 Apr;76(8):4138-44.

43.

Supplemental Content

Loading ...
Support Center